ALX Oncology (NASDAQ:ALXO) Posts Earnings Results

ALX Oncology (NASDAQ:ALXO) issued its quarterly earnings data on Friday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04), Zacks reports.

Here are the key takeaways from ALX Oncology’s conference call:

• Evorpacept (EVO)
• The Phase 2 ASPEN‑09‑Breast trial has been expanded from 80 to up to 120 patients and the primary endpoint was refocused to response rate in CD47‑high patients, with top‑line data for the 80‑patient cohort expected in mid‑2027 and a companion diagnostic in development.
• ALX2004 (EGFR‑targeted ADC) is in dose escalation (now dosing 4 mg/kg after clearing 1 and 2 mg/kg cohorts); company expects full dose‑escalation safety data in H2 2026 and highlights preclinical signals of potent activity with limited ILD/skin toxicity in NHP studies.
• ALX completed an equity financing (gross $150M; net ~$140.4M) and says cash on hand now supports operations through the first half of 2028, strengthening the balance sheet to fund near‑term catalysts across both programs.
• Q4 GAAP net loss narrowed to $22.8M from $29.2M a year earlier and management says spending will be concentrated on EVO and ALX2004 while legacy trials wind down, reducing some near‑term spend but concentrating program risk on two assets.

ALX Oncology Stock Performance

Shares of ALX Oncology stock traded down $0.24 on Friday, reaching $2.11. 1,020,473 shares of the company traded hands, compared to its average volume of 697,137. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.40 and a quick ratio of 2.40. The firm has a market capitalization of $114.40 million, a PE ratio of -1.04 and a beta of 0.51. The company has a 50 day moving average of $1.69 and a 200 day moving average of $1.49. ALX Oncology has a 52 week low of $0.40 and a 52 week high of $2.66.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ALXO. Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a research report on Monday, December 22nd. Piper Sandler raised their price objective on ALX Oncology from $3.00 to $4.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Jefferies Financial Group started coverage on shares of ALX Oncology in a research note on Thursday, November 13th. They issued a “buy” rating and a $4.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, ALX Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $2.50.

Insiders Place Their Bets

In other news, Director Corey S. Goodman bought 3,184,713 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was acquired at an average cost of $1.57 per share, with a total value of $4,999,999.41. Following the completion of the transaction, the director directly owned 8,453,038 shares of the company’s stock, valued at $13,271,269.66. This represents a 60.45% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 21.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ALXO. Invesco Ltd. purchased a new stake in ALX Oncology during the first quarter valued at about $46,000. Bridgeway Capital Management LLC bought a new stake in shares of ALX Oncology in the third quarter valued at approximately $66,000. AQR Capital Management LLC lifted its stake in shares of ALX Oncology by 183.6% during the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after buying an additional 77,065 shares in the last quarter. Jane Street Group LLC bought a new position in ALX Oncology in the 2nd quarter worth approximately $84,000. Finally, State Street Corp boosted its holdings in ALX Oncology by 11.0% in the 4th quarter. State Street Corp now owns 124,228 shares of the company’s stock worth $140,000 after buying an additional 12,300 shares during the period. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.

Featured Stories

• Five stocks we like better than ALX Oncology
• The gold chart Wall Street is terrified of…
• America’s 1776 happening again
• This makes me furious
• Buy this Gold Stock Before May 2026
• What a Former CIA Agent Knows About the Coming Collapse